mechanism-based SAE E1 ligase inhibitor

first-in-class, Ph. II (IV) for adv. solid tumors

from phenotypic screen and scaffold hop

J. Med. Chem., Feb. 25, 2021

Millenium/Takeda, Cambridge, MA

5. The Millenium/Takeda SUMO-activating enzyme (SAE) inhibitor TAK-981 is a mechanism-based inhibitor that covalently forms a SUMO substrate-inhibitor adduct that potently inhibits SAE, rather than reacting with SAE directly.…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks